Bristol-Myers Squibb - Sprycel

Therapeutic Area: Oncology/Hematology
Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders. 

BMS engaged Addison Whitney to name a new medication specific to two indications: treatment of adults in all phases of chronic myeloid leukemia (CML) (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy including Gleevec (imatinib mesylate), and treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) with resistance or intolerance to prior therapy. Ultimately, the brand Sprycel was selected for submission. An extensive research and analysis study was conducted by Addison Whitney in support of the name. The results were presented in a tradename submission document written by Addison Whitney and submitted by the sponsors to the regulatory bodies, which received full FDA approval in 2006.